OBJECTIVE: O⁶-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme. MGMT promoter hypermethylation and epigenetic silencing often occur as early events in carcinogenesis. However, prognostic significance of MGMT alterations in colorectal cancer remains uncertain. METHODS: Utilizing a database of 855 colon and rectal cancers in two prospective cohort studies (the Nurses' Health Study and the Health Professionals Follow-up Study), we detected MGMT promoter hypermethylation in 325 tumors (38%) by MethyLight and loss of MGMT expression in 37% (247/672) of tumors by immunohistochemistry. We assessed the CpG island methylator phenotype (CIMP) using eight methylation markers [CACNA1G, CDKN2A (p16), CRABP1, IGF2, MLH1, NEUROG1, RUNX3, and SOCS1], and LINE-1 (L1) hypomethylation, TP53 (p53), and microsatellite instability (MSI). RESULTS: MGMT hypermethylation was not associated with colorectal cancer-specific mortality in univariate or multivariate Cox regression analysis [adjusted hazard ratio (HR) = 1.03; 95% confidence interval (CI), 0.79-1.36] that adjusted for clinical and tumor features, including CIMP, MSI, and BRAF mutation. Similarly, MGMT loss was not associated with patient survival. MGMT loss was associated with G>A mutations in KRAS (p = 0.019) and PIK3CA (p = 0.0031). CONCLUSIONS: Despite a well-established role of MGMT aberrations in carcinogenesis, neither MGMT promoter methylation nor MGMT loss serves as a prognostic biomarker in colorectal cancer.
OBJECTIVE: O⁶-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme. MGMT promoter hypermethylation and epigenetic silencing often occur as early events in carcinogenesis. However, prognostic significance of MGMT alterations in colorectal cancer remains uncertain. METHODS: Utilizing a database of 855 colon and rectal cancers in two prospective cohort studies (the Nurses' Health Study and the Health Professionals Follow-up Study), we detected MGMT promoter hypermethylation in 325 tumors (38%) by MethyLight and loss of MGMT expression in 37% (247/672) of tumors by immunohistochemistry. We assessed the CpG island methylator phenotype (CIMP) using eight methylation markers [CACNA1G, CDKN2A (p16), CRABP1, IGF2, MLH1, NEUROG1, RUNX3, and SOCS1], and LINE-1 (L1) hypomethylation, TP53 (p53), and microsatellite instability (MSI). RESULTS:MGMT hypermethylation was not associated with colorectal cancer-specific mortality in univariate or multivariate Cox regression analysis [adjusted hazard ratio (HR) = 1.03; 95% confidence interval (CI), 0.79-1.36] that adjusted for clinical and tumor features, including CIMP, MSI, and BRAF mutation. Similarly, MGMT loss was not associated with patient survival. MGMT loss was associated with G>A mutations in KRAS (p = 0.019) and PIK3CA (p = 0.0031). CONCLUSIONS: Despite a well-established role of MGMT aberrations in carcinogenesis, neither MGMT promoter methylation nor MGMT loss serves as a prognostic biomarker in colorectal cancer.
Authors: M Esteller; R A Risques; M Toyota; G Capella; V Moreno; M A Peinado; S B Baylin; J G Herman Journal: Cancer Res Date: 2001-06-15 Impact factor: 12.701
Authors: Lanlan Shen; Yutaka Kondo; Gary L Rosner; Lianchun Xiao; Natalie Supunpong Hernandez; Jill Vilaythong; P Scott Houlihan; Robert S Krouse; Anil R Prasad; Janine G Einspahr; Julie Buckmeier; David S Alberts; Stanley R Hamilton; Jean-Pierre J Issa Journal: J Natl Cancer Inst Date: 2005-09-21 Impact factor: 13.506
Authors: Maija R J Kohonen-Corish; Joseph J Daniel; Charles Chan; Betty P C Lin; Sun Young Kwun; Owen F Dent; Varinderpal S Dhillon; Ronald J A Trent; Pierre H Chapuis; E Leslie Bokey Journal: J Clin Oncol Date: 2005-04-01 Impact factor: 44.544
Authors: M Esteller; M Toyota; M Sanchez-Cespedes; G Capella; M A Peinado; D N Watkins; J P Issa; D Sidransky; S B Baylin; J G Herman Journal: Cancer Res Date: 2000-05-01 Impact factor: 12.701
Authors: Manel Esteller; Gianluca Gaidano; Steven N Goodman; Vittorina Zagonel; Daniela Capello; Barbara Botto; Davide Rossi; Annunziata Gloghini; Umberto Vitolo; Antonino Carbone; Stephen B Baylin; James G Herman Journal: J Natl Cancer Inst Date: 2002-01-02 Impact factor: 13.506
Authors: Takeshi Nagasaka; Gerald B Sharp; Kenji Notohara; Takeshi Kambara; Hiromi Sasamoto; Hiroshi Isozaki; Donald G MacPhee; Jeremy R Jass; Noriaki Tanaka; Nagahide Matsubara Journal: Clin Cancer Res Date: 2003-11-01 Impact factor: 12.531
Authors: Jong-Lyel Roh; Xin Victoria Wang; Judith Manola; David Sidransky; Arlene A Forastiere; Wayne M Koch Journal: Clin Cancer Res Date: 2013-02-26 Impact factor: 12.531